Hanyu Pharmaceuticals and KuCoin have reached a strategic cooperation to explore the innovative drug RWA project

Hanyu Pharmaceuticals and digital asset platform KuCoin have officially signed a letter of intent for a strategic partnership. The two parties intend to jointly explore and promote mainland China's first RWA tokenization pilot project in Hong Kong, with future revenue rights from innovative drug R&D as the underlying asset. Under the agreement, Hanyu Pharmaceuticals will leverage its technological expertise and R&D pipeline in the field of blockbuster GLP-1 peptide drugs as the underlying asset. KuCoin will leverage its expertise in blockchain technology, full-process RWA solutions, and global compliance resources to provide integrated support for the project, including on-chain mapping, asset tokenization, transaction matching, and profit distribution.